-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 8, AnaptysBio announced that the top-line data of the phase II clinical study (POPLAR) of the anti-IL-36R monoclonal antibody imsidolimab for the treatment of moderate to severe palmoplantar pustulosis (PPP) did not meet the primary endpoint.
The results of the study showed that at the 16th week, the PPPASI (palmplantar pustular psoriasis regional severity index) least square mean difference (LSMD) of the Imsidolmab group and the placebo group were 6.
Imsidolmab was well tolerated, and the incidence of adverse events during treatment was similar to that of placebo, and no serious adverse events were observed.
AnaptysBio stated that there is no further plan to continue research on PPP, but it will continue to develop imsidolimab for other 5 immune skin indications, including GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
PPP is a non-fatal pustular psoriasis that accounts for 2% of all psoriasis cases, and there are approximately 150,000 patients in the United States alone.
Imsidolimab is an IL-36R (anti-interleukin 36 receptor) monoclonal antibody developed by AnaptysBio.
Previously, the Phase II interim data of Imsidolimab for the treatment of generalized pustular psoriasis (GPP) achieved positive results, and AnaptysBio plans to launch a Phase III study in mid-2021.
There are not many companies that develop the IL-36 project.
